Tempus launches FDA-approved xT CDx test for solid tumor profiling nationwide.
Read more
OS Therapies' OST-HER2 achieves 33% event-free survival in Phase II trial for lung metastatic osteosarcoma.
Read more
Visby Medical receives $3.9M from CARB-X to enhance PCR-based antibiotic resistance detection.
Read more
PharmAla partners with Merhavim for MDMA trial on PTSD, gaining data license for regulatory use.
Read more
InnoCare and KeyMed license ICP-B02 antibody to Prolium for global non-oncology and ex-Asia oncology development.
Read more
Axcynsis Therapeutics' AT03-65 receives FDA clearance for Phase 1 trial in CLDN6-positive solid tumors.
Read more
Trinity Capital provides $12.5 million growth capital to Upward Health for expansion and care model refinement.
Read more
Fermion and Simcere partner to develop China's first SSTR4 agonist for pain management, entering Phase II trials for Diabetic Neuropathies.
Read more
InflaRx's GOHIBIC® approved by EU for SARS-CoV-2-induced Acute Respiratory Distress Syndrome treatment.
Read more
SightMD Connecticut acquires Doctor & Associates to expand comprehensive eye care services in Fairfield County.
Read more
Avacta's AVA6000 shows promising tumor shrinkage in Phase 1 trial for Salivary Gland Neoplasms.
Read more
PacBio's HiFi sequencing identifies 93% of pathogenic variants in rare diseases, enhancing diagnostic accuracy and efficiency.
Read more
Silver Bullet Therapeutics receives FDA approval for pre-market study of antimicrobial orthopedic implant.
Read more
FDA approves Lilly's Omvoh for Crohn's Disease, expanding treatment options for inflammatory bowel diseases.
Read more
Motif Neurotech receives UK award to develop brain-computer interface for cognitive and psychiatric conditions.
Read more
Telerehabilitation market to grow by USD 532.9 million by 2028, driven by AI and rising chronic disease cases.
Read more
Massive Bio launches $15M AI initiative for cancer trial access, recognized by White House Cancer Moonshot.
Read more
Oncolytics Biotech receives approval to advance pancreatic cancer treatment in GOBLET study after safety review.
Read more
Be Biopharma secures $92M funding to advance Hemophilia B and Hypophosphatasia treatments to clinical stage.
Read more
Zai Lab's TIVDAK shows significant survival benefit in Phase 3 trial for recurrent or metastatic Cervical Cancer in China.
Read more
NAMSA acquires WuXi AppTec's U.S. medical device testing operations, enhancing MedTech testing and clinical research capabilities.
Read more
Cytiva and Cellular Origins partner to automate cell and gene therapy manufacturing for industrial-scale production.
Read more
Johnson & Johnson submits FDA application for TAR-200, a novel treatment for BCG-unresponsive high-risk non-muscle-invasive bladder cancer.
Read more
Attralus begins Phase 3 trial of 124I-evuzamitide for diagnosing Cardiac Amyloidosis with FDA Breakthrough Therapy Designation.
Read more
Over 100 companies advance NSCLC therapies, with FDA breakthrough designations and new clinical trials enhancing treatment options.
Read more
